Bottermann P, Glogger C, Henderkott U
Med Klin. 1979 Oct 12;74(41):1485-91.
15 euthyroid patients, 15 patients with a so-called non toxic goiter, 7 patients with hypothyroidism and 14 patients with hyperthyroidism (Grave's disease and autonomous adenoma) were submitted to intravenous (200 micrograms) and oral (40 mg) TRH-stimulation tests. After the oral application of TRH the patients with a normal thyroid function and the patients with a goiter showed an increase of the concentration of TSH which was about 1 1/2 fold higher than after the intravenous application of TRH. The patients who suffered from hypothyroidism showed a different reaction after intravenous and oral application of TRH. The patients with a hyperthyroidism had neither after the intravenous nor after the oral application of TRH an increase of the peripheral concentration of TSH. Therefore both intravenous and oral TRH-stimulation tests seem to be apt in the same way for the diagnosis of thyroid diseases and for the control of the therapy when thyroid hormones are applied.
15名甲状腺功能正常的患者、15名所谓的非毒性甲状腺肿患者、7名甲状腺功能减退患者和14名甲状腺功能亢进患者(格雷夫斯病和自主性腺瘤)接受了静脉注射(200微克)和口服(40毫克)促甲状腺激素释放激素(TRH)刺激试验。口服TRH后,甲状腺功能正常的患者和甲状腺肿患者的促甲状腺激素(TSH)浓度升高,比静脉注射TRH后高出约1.5倍。甲状腺功能减退患者在静脉注射和口服TRH后表现出不同的反应。甲状腺功能亢进患者在静脉注射和口服TRH后,外周血促甲状腺激素浓度均未升高。因此,静脉注射和口服TRH刺激试验在诊断甲状腺疾病和应用甲状腺激素时控制治疗方面似乎同样适用。